Device Companies Follow New Map To Atrial Fibrillation

Three years ago, the FDA approved Johnson & Johnson’s ThermoCool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to devise new approaches.

In emerging fields of interventional cardiology, success tends to come only after halting progress. In coronary artery disease, angioplasty catheters cleared arteries but elastic recoil caused them to close again, requiring stents to prop them open. Then stents caused an immune reaction leading to restenosis. Drug-eluting stents came along to deal with the new problem. Today, revascularization procedures produce high rates of efficacy. Atrial fibrillation is following a similar path. Earlier versions of radiofrequency catheters overheated tissue, so the tips were irrigated with solution to slow the burn. Irrigation solved one problem but created another – interventionalists no longer could confirm ablation by temperature measurement at the tissue surface. So instead, sensors were developed to measure the force with which the ablation probe contacts tissue so to give physicians feedback about whether they’re creating a competent lesion.

In the case of atrial fibrillation, however, these incremental advancements have so far failed to result in compelling efficacy across...

More from Archive

More from Medtech Insight

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Execs On The Move: June 23–27, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.